RhumbLine Advisers
ROIV icon

RhumbLine Advisers’s Roivant Sciences ROIV Stock Holding History

RhumbLine Advisers’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7M Buy
1,178,789
+65,523
+6% +$1.94M 0.03% 451
2026
Q1 		$30.8M Buy
1,113,266
+75,635
+7% +$1.94M 0.03% 541
2025
Q4 		$22.5M Buy
1,037,631
+9,369
+0.9% +$185K 0.02% 661
2025
Q3 		$15.6M Sell
1,028,262
-1,436
-0.1% -$17.8K 0.01% 875
2025
Q2 		$11.6M Sell
1,029,698
-27,501
-3% -$298K 0.01% 994
2025
Q1 		$10.7M Sell
1,057,199
-17,892
-2% -$193K 0.01% 990
2024
Q4 		$12.7M Sell
1,075,091
-11,498
-1% -$136K 0.01% 939
2024
Q3 		$12.5M Buy
1,086,589
+200,096
+23% +$2.28M 0.01% 958
2024
Q2 		$9.37M Sell
886,493
-70,856
-7% -$776K 0.01% 1057
2024
Q1 		$10.1M Buy
957,349
+535,708
+127% +$5.78M 0.01% 1040
2023
Q4 		$4.73M Buy
421,641
+14,290
+4% +$139K 0.01% 1453
2023
Q3 		$4.76M Buy
407,351
+107,251
+36% +$1.21M 0.01% 1377
2023
Q2 		$3.03M Buy
+300,100
New +$2.68M ﹤0.01% 1679

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RhumbLine Advisers's ROIV Position: Q2 2026 in Review

RhumbLine Advisers increased its Roivant Sciences (ROIV) stake by 5.9% in Q2 2026, buying an estimated $1.94M and bringing the position to 1,178,789 shares worth $41.7M. The position accounts for 0.03% of the portfolio, ranked #451.

RhumbLine Advisers first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • RhumbLine Advisers held 1,178,789 shares of Roivant Sciences worth $41.7M as of Q2 2026.
  • RhumbLine Advisers bought 65,523 Roivant Sciences shares in Q2 2026, an estimated $1.94M.
  • Roivant Sciences made up 0.03% of RhumbLine Advisers's portfolio in Q2 2026, its #451 holding.
  • RhumbLine Advisers first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.